BackArmata Pharmaceuticals Overview

Armata Pharmaceuticals Net Income

Track Armata Pharmaceuticals's net income ($-190M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly Net Income

$74.14M
554.99% YoY

As of Jun 2026

Annual Net Income (TTM)

-$192.18M
647.57% YoY

Trailing 12 months ending Jun 2026

Average Net Income (Comparison Companies)

Loading

Net Income History

Loading

Net Income Comparison

Loading

Annual Net Income Growth Rate (%)

Loading...

Annual Net Income Growth (Absolute)

Loading...

Armata Pharmaceuticals (ARMP) FAQ

Armata Pharmaceuticals (ARMP) currently reports a net income of $-190M as of June 2026. That compares with $-26M in the prior-year period — down 647.6% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Armata Pharmaceuticals's net income history and peer comparisons.

Armata Pharmaceuticals's net income decreased from $-26M to $-190M — a 647.6% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Armata Pharmaceuticals's net income of $-190M is lower than the Healthcare sector average of $16B. That is roughly 101.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Armata Pharmaceuticals reported $-190M in net income as of June 2026. That compares with $-26M in the prior-year period — down 647.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-190M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Armata Pharmaceuticals, and consider following ARMP for alerts when major investors trade the stock.